An analysis of how - and why - oncology remains the hottest area for big-money deals in pharma.
As always, last month's American Society of Clinical Oncology (ASCO) meeting captured a lot of attention from companies and investors, with important new data being presented on Sanofi’s (Euronext: SAN) antibody drug conjugate, Sarclisa (isatuximab) in multiple myeloma, Astellas Pharma (TYO: 4503) Phase III EV-301 trial data with enfortumab vedotin in pre-treated patients with advanced or metastatic urothelial cancer, as well as data from newcomers including I-Mab (Nasdaq: IMAB) with its new CD73 antibody uliledlimab in combination with Roche’s (ROG:SIX) Tecentriq in patients with advanced cancer, and Adicet Bio's (Nasdaq: ACET) off the shelf gamma-delta T-cell therapy ADI-001, in lymphoma.
So why is there such continued interest and investment in oncology?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze